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Abstract
Synovial sarcoma (SS) comprises less than 1% of head and neck cancers, and less than ﬁve cases of adult primary tracheal SS have
been described. This case describes a patient encountered at a community-based academic hospital, and retrospective chart
review was performed for data collection. A woman in her forties presented with shortness of breath due to a superior
mediastinal mass found to be an unresectable primary tracheal SS. Primary treatment resorted to curative-intent radiation
therapy. Subsequent metastasis required systemic chemotherapy with pazopanib. To the best of our knowledge, this is the ﬁrst
reported case of this nature and adds to understanding the presentation, diagnosis, natural history, and treatment outcomes of
primary tracheal SS. This case was exempt from review by the institutional review board and complied with privacy policy
standards.
Keywords
Synovial sarcoma, Unresectable, Tracheal sarcoma, Head and neck cancer

Introduction
Soft tissue sarcomas comprise approximately 1% of head and
neck cancers, and synovial sarcoma (SS) comprises only a
fraction of those cases.1 Primary tracheal SS is exceedingly
rare, with only 5 adult cases reported.2-5 Tumors are considered unresectable if they involve greater than half the length
of the trachea or invade critical mediastinal structures, and
their treatment resorts to primary radiation therapy (RT) rather
than surgical resection.1 We present a case of unresectable
primary tracheal SS that subsequently metastasized and required systemic chemotherapy. Though the treatments were
not novel in oncologic care, this case is unique among other
reports of primary tracheal SS in that it was unresectable and
metastasized after primary treatment. This case report presents
the treatment response and survival outcome of previously
undescribed unresectable primary tracheal SS.

that showed atelectasis of the left lower lobe and narrowing of
the left main bronchus from a 36×30.3×40.3 mm superior
mediastinal mass. The mass had irregular margins and central
hypodensity suggestive of complex ﬂuid or necrotic material
(Figure 1). The patient was intubated before undergoing MRI
that showed a 1 cm increase in mass size since imaging 5 years
prior. Bronchoscopy identiﬁed a fungating, friable mass obstructing greater than 80% of the tracheal lumen. Cytology
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Case Report
A woman in her 40s presented with worsening wheezing and
shortness of breath. Workup included chest CT angiography
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Figure 1. Chest X-ray (A) and CT scan (B,C) with a yellow arrowing indicating the superior mediastinal mass.

revealed a spindle cell neoplasm with necrosis, and pathology showed a malignant round blue cell neoplasm.
Histopathologic and immunohistochemical staining
showed a poorly differentiated SS (Table 1). Fluorescence
in-situ hybridization panel and molecular marker results
were negative for SS18 and EWSR1. However, a genetic
fusion panel showed the pathognomonic SS18-SSX fusion
on next generation sequencing analysis, conﬁrming the
diagnosis of SS. The tumor was unresectable due to mediastinal extension, and the patient underwent repeat
debulking with tracheal stent placement before extubation
and discharge. Initial metastasis workup was unremarkable, and she completed curative-intent RT using a total
dose of 50 Gray (Gy) at 2 Gy/fraction with restoration of
the airway diameter. Two months later, PET CT showed
bone and lung metastasis, and the patient began systemic
therapy with pazopanib 400 mg daily 8 months after initial
presentation.

Discussion
To the best of our knowledge, this case presents the ﬁrst
documented unresectable primary tracheal SS. Primary
tracheal SS is exceedingly rare, and no treatment guidelines
currently exist. However, surgical resection is the treatment
of choice for other head and neck sarcomas, with adjuvant
RT reserved for recurrent or intermediate- to high-grade
tumors.1 Treatment of unresectable cases includes RT and
confers a worse prognosis than treatments including
surgery.1

Table 1. Pathology Results for Immunohistochemical (IHC) Staining
of the Superior Mediastinal Mass Biopsy.
IHC marker

Result

TLE-1
CD99, CD138
FLI-1
CD3, CD20, CD30, CD34, CD45
Cytokeratin
S100
HMB45
TdTT
STAT6
Ki67

Diffusely positive
Weakly positive
Negative

50%

Current literature on primary tracheal SS suggests that
treatments used in other head and neck sarcomas are effective.
Corrales et al. (2011) and Kumar et al. (2020) report cases of
primary tracheal SS in 48-year-old and 26-year-old women,
respectively. Both underwent surgical resection and maintained locoregional control without metastasis for 1 year.2,3
Sykes et al. (1997) described primary tracheal SS in a 20-yearold man who underwent surgical resection and 62 Gy of
external beam RT and remained well 8 months post-op.4 Ye
et al. (2020) report primary tracheal SS in a 19-year-old man
treated with surgical resection and 63 Gy of adjuvant proton
beam therapy who remained without recurrence for
18 months.5
Ultimately, current literature suggests that treatment protocols for other head and neck sarcomas confer a reasonable
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prognosis in primary tracheal SS. The mediastinal invasion
of our patient’s tumor deemed it unresectable, and treatment
resorted to RT. Despite excellent initial response, the tumor
metastasized and required systemic chemotherapy. This case
presented the ﬁrst of unfavorable outcomes reported in
primary tracheal SS. There are no guidelines for the treatment of primary tracheal SS, though surgical resection could
be considered the treatment of choice and is supported by
favorable outcomes in reported cases. This case presented
an unresectable primary tracheal SS that initially demonstrated favorable response to second-line therapy but
subsequently metastasized and required systemic treatment.
It contributes to the understanding of the presentation,
diagnosis, natural history, and treatment outcomes of primary tracheal SS.
Authors Contributions
Joann M. Butkus: study design, data collection, analysis, and article
writing/editing.
Mackenzie Kramer: study design, data collection, and article writing/
editing.
Daniel Eichorn: data collection and article writing/editing.
Ali Raza R. Shaikh: data collection.
Rajesh R. Patel: article writing/editing.

Declaration of Conﬂicting Interests
The author(s) declared no potential conﬂicts of interest with
respect to the research, authorship, and/or publication of this
article.

3

Funding
The author(s) received no ﬁnancial support for the research, authorship, and/or publication of this article.

Ethics Statement
This report was exempt from review by Thomas Jefferson University’s institutional review board and complies with all privacy
policy standards.

ORCID iD
Joann M. Butkus  https://orcid.org/0000-0002-4076-3024

References
1. O’Niell JP, Bilsky MH, Kraus D. Head and neck sarcomas:
epidemiology, pathology, and management. Neurosurg Clin of
North Am. 2013;24(1):67-78.
2. Corrales C, Berry G, Damrose E. Primary cervical tracheal
monophasic synovial sarcoma conﬁrmed by SYT-SSX gene
rearrangement. J Laryngol Otol. 2011;125(6):651-654.
3. Kumar N, Kaushal S, Kanaklata K, Gowda M, Kumar S. Primary
tracheal synovial sarcoma: a rare clinical entity with diagnostic
challenges. J Egyptian Nat Canc Instit. 2020;32(3).
4. Sykes A, Rokkas C, Kajdacsy-Balla A, Haasler GB. Primary
tracheal synovial cell sarcoma: a ﬁrst case report. J Thorac
Cariovasc Surg. 1997;114(4):678-680.
5. Ye C, Guo J, Liu X, Jiang G, Wang W. Surgery and proton beam
therapy for tracheal synovial sarcoma. Ann Thorac Surg. 2020;
110(4):e265-e267.

